ID   SPHM_HUMAN              Reviewed;         502 AA.
AC   P51688; A8K5E2;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 154.
DE   RecName: Full=N-sulphoglucosamine sulphohydrolase;
DE            EC=3.10.1.1 {ECO:0000269|PubMed:15146460, ECO:0000269|PubMed:24816101, ECO:0000269|PubMed:7493035};
DE   AltName: Full=Sulfoglucosamine sulfamidase;
DE   AltName: Full=Sulphamidase;
DE   Flags: Precursor;
GN   Name=SGSH; Synonyms=HSS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 21-45, CATALYTIC
RP   ACTIVITY, AND FUNCTION.
RC   TISSUE=Kidney, and Testis;
RX   PubMed=7493035; DOI=10.1038/ng1295-465;
RA   Scott H.S., Blanch L., Guo X.-H., Freeman C., Orsborn A., Baker E.,
RA   Sutherland G.R., Morris C.P., Hopwood J.J.;
RT   "Cloning of the sulphamidase gene and identification of mutations in
RT   Sanfilippo A syndrome.";
RL   Nat. Genet. 11:465-467(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Karageorgos L.E., Guo X.H., Blanch L., Weber B., Anson D.S.,
RA   Scott H.S., Hopwood J.J.;
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   GLYCOSYLATION AT ASN-41 AND ASN-264.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [6]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-41 AND ASN-413.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH CALCIUM,
RP   FUNCTION, CATALYTIC ACTIVITY, GLYCOSYLATION AT ASN-41; ASN-151;
RP   ASN-264 AND ASN-413, OXOALANINE AT CYS-70, DISULFIDE BONDS, AND
RP   FORMYLGLYCINE.
RX   PubMed=24816101; DOI=10.1107/S1399004714002739;
RA   Sidhu N.S., Schreiber K., Propper K., Becker S., Uson I.,
RA   Sheldrick G.M., Gartner J., Kratzner R., Steinfeld R.;
RT   "Structure of sulfamidase provides insight into the molecular
RT   pathology of mucopolysaccharidosis IIIA.";
RL   Acta Crystallogr. D 70:1321-1335(2014).
RN   [9]
RP   VARIANTS MPS3A, AND VARIANT HIS-456.
RX   PubMed=9158154; DOI=10.1093/hmg/6.5.787;
RA   Blanch L., Weber B., Guo X.-H., Scott H.S., Hopwood J.J.;
RT   "Molecular defects in Sanfilippo syndrome type A.";
RL   Hum. Mol. Genet. 6:787-791(1997).
RN   [10]
RP   VARIANTS MPS3A.
RX   PubMed=9285796; DOI=10.1093/hmg/6.9.1573;
RA   Weber B., Guo X.-H., Wraith J.E., Cooper A., Kleijer W.J., Bunge S.,
RA   Hopwood J.J.;
RT   "Novel mutations in Sanfilippo A syndrome: implications for enzyme
RT   function.";
RL   Hum. Mol. Genet. 6:1573-1579(1997).
RN   [11]
RP   VARIANTS MPS3A.
RX   PubMed=9401012;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:6<479::AID-HUMU10>3.0.CO;2-X;
RA   Bunge S., Ince H., Steglich C., Kleijer W.J., Beck M., Zaremba J.,
RA   van Diggelen O.P., Weber B., Hopwood J.J., Gal A.;
RT   "Identification of 16 sulfamidase gene mutations including the common
RT   R74C in patients with mucopolysaccharidosis type IIIA (Sanfilippo
RT   A).";
RL   Hum. Mutat. 10:479-485(1997).
RN   [12]
RP   VARIANTS MPS3A ASN-40; THR-44; TRP-66; CYS-74; ARG-122; LEU-128;
RP   PRO-146; GLN-150; ASN-179; CYS-182; ARG-227; LYS-369 AND CYS-377, AND
RP   VARIANTS ALA-226 AND HIS-456.
RX   PubMed=9554748;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<313::AID-HUMU9>3.3.CO;2-G;
RA   di Natale P., Balzano N., Esposito S., Villani G.R.D.;
RT   "Identification of molecular defects in Italian Sanfilippo A patients
RT   including 13 novel mutations.";
RL   Hum. Mutat. 11:313-320(1998).
RN   [13]
RP   VARIANTS MPS3A ARG-85; PRO-206; PRO-354 AND ARG-386.
RX   PubMed=9744479;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:4<274::AID-HUMU9>3.3.CO;2-Y;
RA   Montfort M., Vilageliu L., Garcia-Giralt N., Guidi S., Coll M.J.,
RA   Chabas A., Grinberg D.;
RT   "Mutation 1091delC is highly prevalent in Spanish Sanfilippo syndrome
RT   type A patients.";
RL   Hum. Mutat. 12:274-279(1998).
RN   [14]
RP   VARIANTS MPS3A GLY-32; TRP-66; CYS-74; PRO-79; TYR-84; ARG-122;
RP   TRP-150; ASN-235; HIS-245; ASN-273; PRO-298; SER-322; LYS-355;
RP   HIS-374; GLN-ARG-381 INS; TRP-433; 436-TRP--LEU-438 DEL AND PHE-486,
RP   AND VARIANT HIS-456.
RX   PubMed=11182930; DOI=10.1136/jmg.37.9.704;
RA   Beesley C.E., Young E.P., Vellodi A., Winchester B.G.;
RT   "Mutational analysis of Sanfilippo syndrome type A (MPS IIIA):
RT   identification of 13 novel mutations.";
RL   J. Med. Genet. 37:704-707(2000).
RN   [15]
RP   VARIANTS MPS3A LYS-42; ASN-235; SER-293 AND CYS-377, VARIANT HIS-456,
RP   CHARACTERIZATION OF VARIANTS MPS3A LYS-42; ASN-235; SER-293 AND
RP   CYS-377, AND CHARACTERIZATION OF VARIANT HIS-456.
RX   PubMed=12000360; DOI=10.1034/j.1399-0004.2002.610304.x;
RA   Lee-Chen G.J., Lin S.P., Ko M.H., Chuang C.K., Chen C.P., Lee H.H.,
RA   Cheng S.C., Shen C.H., Tseng K.L., Li C.L.;
RT   "Identification and characterization of mutations underlying
RT   Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA).";
RL   Clin. Genet. 61:192-197(2002).
RN   [16]
RP   VARIANTS MPS3A CYS-74 AND SER-288.
RX   PubMed=11793481; DOI=10.1002/humu.9009;
RA   Emre S., Terzioglu M., Tokatli A., Coskun T., Ozalp I., Weber B.,
RA   Hopwood J.J.;
RT   "Sanfilippo syndrome in Turkey: identification of novel mutations in
RT   subtypes A and B.";
RL   Hum. Mutat. 19:184-185(2002).
RN   [17]
RP   VARIANTS MPS3A LEU-128; LYS-369 AND GLN-433, AND VARIANT HIS-456.
RX   PubMed=12702166; DOI=10.1034/j.1399-0004.2003.00053.x;
RA   Di Natale P., Villani G.R.D., Di Domenico C., Daniele A.,
RA   Dionisi Vici C., Bartuli A.;
RT   "Analysis of Sanfilippo A gene mutations in a large pedigree.";
RL   Clin. Genet. 63:314-318(2003).
RN   [18]
RP   VARIANTS MPS3A CYS-74; ARG-106; PRO-163; ARG-191; TYR-403 DEL AND
RP   TRP-433, CHARACTERIZATION OF VARIANTS MPS3A CYS-74; ARG-106; PRO-163;
RP   ARG-191; TYR-403 DEL AND TRP-433, CATALYTIC ACTIVITY, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15146460; DOI=10.1002/humu.20037;
RA   Muschol N., Storch S., Ballhausen D., Beesley C., Westermann J.-C.,
RA   Gal A., Ullrich K., Hopwood J.J., Winchester B., Braulke T.;
RT   "Transport, enzymatic activity, and stability of mutant sulfamidase
RT   (SGSH) identified in patients with mucopolysaccharidosis type III A.";
RL   Hum. Mutat. 23:559-566(2004).
RN   [19]
RP   VARIANT MPS3A PRO-206, VARIANT HIS-456, AND CHARACTERIZATION OF
RP   VARIANT MPS3A PRO-206.
RX   PubMed=15637719; DOI=10.1002/ajmg.a.30552;
RA   Gabrielli O., Coppa G.V., Bruni S., Villani G.R.D., Pontarelli G.,
RA   Di Natale P.;
RT   "An adult Sanfilippo type A patient with homozygous mutation R206P in
RT   the sulfamidase gene.";
RL   Am. J. Med. Genet. A 133:85-89(2005).
RN   [20]
RP   VARIANTS MPS3A VAL-300 AND PRO-307.
RX   PubMed=15902564; DOI=10.1007/s10545-005-0601-0;
RA   Bekri S., Armana G., De Ricaud D., Osenda M., Maire I.,
RA   Van Obberghen E., Froissart R.;
RT   "Early diagnosis of mucopolysaccharidosis III A with a nonsense
RT   mutation and two de novo missense mutations in SGSH gene.";
RL   J. Inherit. Metab. Dis. 28:601-602(2005).
RN   [21]
RP   VARIANT MPS3A THR-293, AND VARIANTS LEU-304 AND MET-387.
RX   PubMed=17128482;
RA   Di Natale P., Pontarelli G., Villani G.R.D., Di Domenico C.;
RT   "Gene symbol: SGSH. Disease: Sanfilippo type A syndrome,
RT   mucopolysaccharidosis IIIA.";
RL   Hum. Genet. 119:679-679(2006).
RN   [22]
RP   VARIANT MPS3A THR-88.
RX   PubMed=16311287; DOI=10.1093/humrep/dei382;
RA   Fiorentino F., Biricik A., Nuccitelli A., De Palma R., Kahraman S.,
RA   Iacobelli M., Trengia V., Caserta D., Bonu M.A., Borini A., Baldi M.;
RT   "Strategies and clinical outcome of 250 cycles of Preimplantation
RT   Genetic Diagnosis for single gene disorders.";
RL   Hum. Reprod. 21:670-684(2006).
RN   [23]
RP   VARIANTS MPS3A GLU-32; CYS-74; HIS-245; ALA-251 AND PRO-298, AND
RP   ASSOCIATION OF VARIANT MPS3A PRO-298 WITH SLOWLY PROGRESSIVE
RP   PHENOTYPE.
RX   PubMed=18407553; DOI=10.1002/humu.20738;
RA   Meyer A., Kossow K., Gal A., Steglich C., Muehlhausen C., Ullrich K.,
RA   Braulke T., Muschol N.;
RT   "The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is
RT   associated with a slowly progressive clinical phenotype in
RT   mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).";
RL   Hum. Mutat. 29:770-770(2008).
RN   [24]
RP   VARIANTS MPS3A TRP-66; CYS-74; HIS-245; ALA-251 AND PRO-298, AND
RP   CHARACTERIZATION OF VARIANT MPS3A PRO-298.
RX   PubMed=21671382; DOI=10.1002/ajmg.a.34053;
RA   Muschol N., Pohl S., Meyer A., Gal A., Ullrich K., Braulke T.;
RT   "Residual activity and proteasomal degradation of p.Ser298Pro
RT   sulfamidase identified in patients with a mild clinical phenotype of
RT   Sanfilippo A syndrome.";
RL   Am. J. Med. Genet. A 155A:1634-1639(2011).
CC   -!- FUNCTION: Catalyzes a step in lysosomal heparan sulfate
CC       degradation. {ECO:0000269|PubMed:15146460,
CC       ECO:0000269|PubMed:24816101, ECO:0000269|PubMed:7493035}.
CC   -!- CATALYTIC ACTIVITY: N-sulfo-D-glucosamine + H(2)O = D-glucosamine
CC       + sulfate. {ECO:0000269|PubMed:15146460,
CC       ECO:0000269|PubMed:24816101, ECO:0000269|PubMed:7493035}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:24816101};
CC       Note=Binds 1 Ca(2+) ion per subunit.
CC       {ECO:0000269|PubMed:24816101};
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000269|PubMed:15146460}.
CC   -!- PTM: The conversion to 3-oxoalanine (also known as C-
CC       formylglycine, FGly), of a serine or cysteine residue in
CC       prokaryotes and of a cysteine residue in eukaryotes, is critical
CC       for catalytic activity. {ECO:0000269|PubMed:24816101}.
CC   -!- DISEASE: Mucopolysaccharidosis 3A (MPS3A) [MIM:252900]: A severe
CC       form of mucopolysaccharidosis type 3, an autosomal recessive
CC       lysosomal storage disease due to impaired degradation of heparan
CC       sulfate. MPS3 is characterized by severe central nervous system
CC       degeneration, but only mild somatic disease. Onset of clinical
CC       features usually occurs between 2 and 6 years; severe neurologic
CC       degeneration occurs in most patients between 6 and 10 years of
CC       age, and death occurs typically during the second or third decade
CC       of life. MPS3A is characterized by earlier onset, rapid
CC       progression of symptoms and shorter survival.
CC       {ECO:0000269|PubMed:11182930, ECO:0000269|PubMed:11793481,
CC       ECO:0000269|PubMed:12000360, ECO:0000269|PubMed:12702166,
CC       ECO:0000269|PubMed:15146460, ECO:0000269|PubMed:15637719,
CC       ECO:0000269|PubMed:15902564, ECO:0000269|PubMed:16311287,
CC       ECO:0000269|PubMed:17128482, ECO:0000269|PubMed:18407553,
CC       ECO:0000269|PubMed:21671382, ECO:0000269|PubMed:9158154,
CC       ECO:0000269|PubMed:9285796, ECO:0000269|PubMed:9401012,
CC       ECO:0000269|PubMed:9554748, ECO:0000269|PubMed:9744479}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the sulfatase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U30894; AAA86530.1; -; mRNA.
DR   EMBL; U60111; AAB17952.1; -; Genomic_DNA.
DR   EMBL; U60107; AAB17952.1; JOINED; Genomic_DNA.
DR   EMBL; U60108; AAB17952.1; JOINED; Genomic_DNA.
DR   EMBL; U60109; AAB17952.1; JOINED; Genomic_DNA.
DR   EMBL; U60110; AAB17952.1; JOINED; Genomic_DNA.
DR   EMBL; AK291257; BAF83946.1; -; mRNA.
DR   EMBL; BC047318; AAH47318.1; -; mRNA.
DR   CCDS; CCDS11770.1; -.
DR   RefSeq; NP_000190.1; NM_000199.3.
DR   UniGene; Hs.31074; -.
DR   PDB; 4MHX; X-ray; 2.00 A; A/B=1-502.
DR   PDB; 4MIV; X-ray; 2.40 A; A/B/C/D/E/F/G/H=1-502.
DR   PDBsum; 4MHX; -.
DR   PDBsum; 4MIV; -.
DR   ProteinModelPortal; P51688; -.
DR   SMR; P51688; -.
DR   BioGrid; 112346; 11.
DR   IntAct; P51688; 1.
DR   STRING; 9606.ENSP00000314606; -.
DR   iPTMnet; P51688; -.
DR   PhosphoSitePlus; P51688; -.
DR   BioMuta; SGSH; -.
DR   EPD; P51688; -.
DR   MaxQB; P51688; -.
DR   PaxDb; P51688; -.
DR   PeptideAtlas; P51688; -.
DR   PRIDE; P51688; -.
DR   Ensembl; ENST00000326317; ENSP00000314606; ENSG00000181523.
DR   GeneID; 6448; -.
DR   KEGG; hsa:6448; -.
DR   UCSC; uc002jxz.5; human.
DR   CTD; 6448; -.
DR   DisGeNET; 6448; -.
DR   GeneCards; SGSH; -.
DR   HGNC; HGNC:10818; SGSH.
DR   HPA; HPA023436; -.
DR   HPA; HPA023451; -.
DR   MalaCards; SGSH; -.
DR   MIM; 252900; phenotype.
DR   MIM; 605270; gene.
DR   neXtProt; NX_P51688; -.
DR   OpenTargets; ENSG00000181523; -.
DR   Orphanet; 79269; Sanfilippo syndrome type A.
DR   PharmGKB; PA35726; -.
DR   eggNOG; KOG3867; Eukaryota.
DR   eggNOG; COG3119; LUCA.
DR   GeneTree; ENSGT00390000013080; -.
DR   HOGENOM; HOG000234731; -.
DR   HOVERGEN; HBG012598; -.
DR   InParanoid; P51688; -.
DR   KO; K01565; -.
DR   OMA; KEDRHHE; -.
DR   OrthoDB; EOG091G073U; -.
DR   PhylomeDB; P51688; -.
DR   TreeFam; TF323156; -.
DR   BRENDA; 3.10.1.1; 2681.
DR   Reactome; R-HSA-2024096; HS-GAG degradation.
DR   ChiTaRS; SGSH; human.
DR   GeneWiki; SGSH; -.
DR   GenomeRNAi; 6448; -.
DR   PRO; PR:P51688; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000181523; -.
DR   CleanEx; HS_SGSH; -.
DR   ExpressionAtlas; P51688; baseline and differential.
DR   Genevisible; P51688; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016250; F:N-sulfoglucosamine sulfohydrolase activity; IDA:UniProtKB.
DR   GO; GO:0008484; F:sulfuric ester hydrolase activity; IEA:Ensembl.
DR   GO; GO:0006027; P:glycosaminoglycan catabolic process; IDA:UniProtKB.
DR   GO; GO:0030200; P:heparan sulfate proteoglycan catabolic process; IMP:UniProtKB.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR032506; DUF4976.
DR   InterPro; IPR024607; Sulfatase_CS.
DR   InterPro; IPR000917; Sulfatase_N.
DR   Pfam; PF16347; DUF4976; 1.
DR   Pfam; PF00884; Sulfatase; 1.
DR   SUPFAM; SSF53649; SSF53649; 2.
DR   PROSITE; PS00523; SULFATASE_1; 1.
DR   PROSITE; PS00149; SULFATASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Hydrolase; Lysosome;
KW   Metal-binding; Mucopolysaccharidosis; Polymorphism;
KW   Reference proteome; Signal.
FT   SIGNAL        1     20       {ECO:0000269|PubMed:7493035}.
FT   CHAIN        21    502       N-sulphoglucosamine sulphohydrolase.
FT                                /FTId=PRO_0000033433.
FT   COMPBIAS     26     29       Poly-Leu.
FT   METAL        31     31       Calcium. {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:24816101}.
FT   METAL        32     32       Calcium. {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:24816101}.
FT   METAL        70     70       Calcium; via 3-oxoalanine.
FT                                {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:24816101}.
FT   METAL       273    273       Calcium. {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:24816101}.
FT   METAL       274    274       Calcium. {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:24816101}.
FT   MOD_RES      70     70       3-oxoalanine (Cys).
FT                                {ECO:0000269|PubMed:24816101}.
FT   CARBOHYD     41     41       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:24816101}.
FT   CARBOHYD    142    142       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    151    151       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:24816101}.
FT   CARBOHYD    264    264       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:24816101}.
FT   CARBOHYD    413    413       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:24816101}.
FT   DISULFID    183    194       {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:24816101}.
FT   DISULFID    481    495       {ECO:0000244|PDB:4MHX,
FT                                ECO:0000244|PDB:4MIV,
FT                                ECO:0000269|PubMed:24816101}.
FT   VARIANT      32     32       D -> E (in MPS3A).
FT                                {ECO:0000269|PubMed:18407553}.
FT                                /FTId=VAR_054670.
FT   VARIANT      32     32       D -> G (in MPS3A).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054671.
FT   VARIANT      40     40       Y -> N (in MPS3A; intermediate).
FT                                {ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007388.
FT   VARIANT      42     42       N -> K (in MPS3A; does not yield active
FT                                enzyme; the reduction in 62 kDa precursor
FT                                and 56 kDa mature forms suggests an
FT                                increased degradation of the mutant
FT                                enzyme). {ECO:0000269|PubMed:12000360}.
FT                                /FTId=VAR_054672.
FT   VARIANT      44     44       A -> T (in MPS3A; severe).
FT                                {ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007389.
FT   VARIANT      66     66       S -> W (in MPS3A; intermediate/severe;
FT                                common mutation in Italy;
FT                                dbSNP:rs104894637).
FT                                {ECO:0000269|PubMed:11182930,
FT                                ECO:0000269|PubMed:21671382,
FT                                ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007390.
FT   VARIANT      74     74       R -> C (in MPS3A; intermediate/severe;
FT                                the mutant is enzymatically inactive;
FT                                rapid degradation rather than decrease in
FT                                synthesis is responsible for the low
FT                                steady state level of the mutant protein
FT                                in cells; the majority of newly
FT                                synthesized protein probably occurs in
FT                                the endoplasmic reticulum;
FT                                dbSNP:rs104894636).
FT                                {ECO:0000269|PubMed:11182930,
FT                                ECO:0000269|PubMed:11793481,
FT                                ECO:0000269|PubMed:15146460,
FT                                ECO:0000269|PubMed:18407553,
FT                                ECO:0000269|PubMed:21671382,
FT                                ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007391.
FT   VARIANT      74     74       R -> H (in MPS3A; dbSNP:rs778336949).
FT                                /FTId=VAR_007392.
FT   VARIANT      79     79       T -> P (in MPS3A; severe;
FT                                dbSNP:rs779703983).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_007393.
FT   VARIANT      84     85       Missing (in MPS3A).
FT                                /FTId=VAR_007394.
FT   VARIANT      84     84       H -> Y (in MPS3A).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054673.
FT   VARIANT      85     85       Q -> R (in MPS3A).
FT                                {ECO:0000269|PubMed:9744479}.
FT                                /FTId=VAR_007395.
FT   VARIANT      88     88       M -> T (in MPS3A).
FT                                {ECO:0000269|PubMed:16311287}.
FT                                /FTId=VAR_054674.
FT   VARIANT      90     90       G -> R (in MPS3A; dbSNP:rs774010006).
FT                                /FTId=VAR_007396.
FT   VARIANT     106    106       S -> R (in MPS3A; shows 3.3% activity of
FT                                the expressed wild-type enzyme; rapid
FT                                degradation rather than decrease in
FT                                synthesis is responsible for the low
FT                                steady state level of the mutant protein
FT                                in cells). {ECO:0000269|PubMed:15146460}.
FT                                /FTId=VAR_054675.
FT   VARIANT     122    122       G -> R (in MPS3A; intermediate;
FT                                dbSNP:rs761607612).
FT                                {ECO:0000269|PubMed:11182930,
FT                                ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007397.
FT   VARIANT     128    128       P -> L (in MPS3A; intermediate;
FT                                dbSNP:rs104894642).
FT                                {ECO:0000269|PubMed:12702166,
FT                                ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007398.
FT   VARIANT     131    131       V -> M (in MPS3A; dbSNP:rs370636303).
FT                                /FTId=VAR_007399.
FT   VARIANT     139    139       T -> M (in MPS3A; dbSNP:rs775112689).
FT                                /FTId=VAR_007400.
FT   VARIANT     146    146       L -> P (in MPS3A; severe;
FT                                dbSNP:rs749358773).
FT                                {ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007401.
FT   VARIANT     150    150       R -> Q (in MPS3A; severe;
FT                                dbSNP:rs104894638).
FT                                {ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007402.
FT   VARIANT     150    150       R -> W (in MPS3A).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054676.
FT   VARIANT     163    163       L -> P (in MPS3A; the mutant is
FT                                enzymatically inactive; rapid degradation
FT                                rather than decrease in synthesis is
FT                                responsible for the low steady state
FT                                level of the mutant protein in cells; the
FT                                mutant protein shows instability in the
FT                                lysosomes).
FT                                {ECO:0000269|PubMed:15146460}.
FT                                /FTId=VAR_054677.
FT   VARIANT     179    179       D -> N (in MPS3A; severe;
FT                                dbSNP:rs774773010).
FT                                {ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007403.
FT   VARIANT     182    182       R -> C (in MPS3A; intermediate;
FT                                dbSNP:rs529855742).
FT                                {ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007404.
FT   VARIANT     191    191       G -> R (in MPS3A; the mutant is
FT                                enzymatically inactive; rapid degradation
FT                                rather than decrease in synthesis is
FT                                responsible for the low steady state
FT                                level of the mutant protein in cells; the
FT                                majority of newly synthesized protein
FT                                probably occurs in the endoplasmic
FT                                reticulum; dbSNP:rs753666460).
FT                                {ECO:0000269|PubMed:15146460}.
FT                                /FTId=VAR_054678.
FT   VARIANT     193    193       F -> L (in MPS3A).
FT                                /FTId=VAR_007405.
FT   VARIANT     206    206       R -> P (in MPS3A; the mutant enzyme
FT                                retains 8% residual activity;
FT                                dbSNP:rs104894643).
FT                                {ECO:0000269|PubMed:15637719,
FT                                ECO:0000269|PubMed:9744479}.
FT                                /FTId=VAR_007406.
FT   VARIANT     226    226       V -> A. {ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007407.
FT   VARIANT     227    227       P -> R (in MPS3A; severe;
FT                                dbSNP:rs774602372).
FT                                {ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007408.
FT   VARIANT     234    234       A -> G (in MPS3A; dbSNP:rs113641837).
FT                                /FTId=VAR_007409.
FT   VARIANT     235    235       D -> N (in MPS3A; does not yield active
FT                                enzyme; the reduction in 62 kDa precursor
FT                                and 56 kDa mature forms suggests an
FT                                increased degradation of the mutant
FT                                enzyme; dbSNP:rs753472891).
FT                                {ECO:0000269|PubMed:11182930,
FT                                ECO:0000269|PubMed:12000360}.
FT                                /FTId=VAR_054679.
FT   VARIANT     235    235       D -> V (in MPS3A; dbSNP:rs763800418).
FT                                /FTId=VAR_007410.
FT   VARIANT     245    245       R -> H (in MPS3A; severe; common mutation
FT                                in Western Europe and Australia;
FT                                dbSNP:rs104894635).
FT                                {ECO:0000269|PubMed:11182930,
FT                                ECO:0000269|PubMed:18407553,
FT                                ECO:0000269|PubMed:21671382}.
FT                                /FTId=VAR_007411.
FT   VARIANT     251    251       G -> A (in MPS3A; dbSNP:rs144461610).
FT                                {ECO:0000269|PubMed:18407553,
FT                                ECO:0000269|PubMed:21671382}.
FT                                /FTId=VAR_054680.
FT   VARIANT     273    273       D -> N (in MPS3A).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054681.
FT   VARIANT     288    288       P -> S (in MPS3A).
FT                                {ECO:0000269|PubMed:11793481}.
FT                                /FTId=VAR_054682.
FT   VARIANT     293    293       P -> S (in MPS3A; does not yield active
FT                                enzyme; the reduction in 62 kDa precursor
FT                                and 56 kDa mature forms suggests an
FT                                increased degradation of the mutant
FT                                enzyme; dbSNP:rs143947056).
FT                                {ECO:0000269|PubMed:12000360}.
FT                                /FTId=VAR_054683.
FT   VARIANT     293    293       P -> T (in MPS3A).
FT                                {ECO:0000269|PubMed:17128482}.
FT                                /FTId=VAR_054684.
FT   VARIANT     298    298       S -> P (in MPS3A; associated with a
FT                                slowly progressive clinical phenotype;
FT                                rapidly degraded but small amounts of the
FT                                mutant protein are correctly transported
FT                                to the lysosome; low but significant
FT                                residual enzymatic activity;
FT                                dbSNP:rs138504221).
FT                                {ECO:0000269|PubMed:11182930,
FT                                ECO:0000269|PubMed:18407553,
FT                                ECO:0000269|PubMed:21671382}.
FT                                /FTId=VAR_007412.
FT   VARIANT     300    300       E -> V (in MPS3A).
FT                                {ECO:0000269|PubMed:15902564}.
FT                                /FTId=VAR_054685.
FT   VARIANT     304    304       R -> L (in dbSNP:rs745884647).
FT                                {ECO:0000269|PubMed:17128482}.
FT                                /FTId=VAR_054686.
FT   VARIANT     307    307       Q -> P (in MPS3A).
FT                                {ECO:0000269|PubMed:15902564}.
FT                                /FTId=VAR_054687.
FT   VARIANT     321    321       T -> A (in MPS3A; dbSNP:rs758756630).
FT                                /FTId=VAR_007413.
FT   VARIANT     322    322       I -> S (in MPS3A).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054688.
FT   VARIANT     354    354       A -> P (in MPS3A).
FT                                {ECO:0000269|PubMed:9744479}.
FT                                /FTId=VAR_007414.
FT   VARIANT     355    355       E -> K (in MPS3A; dbSNP:rs766938111).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054689.
FT   VARIANT     361    361       V -> I (in dbSNP:rs9894254).
FT                                /FTId=VAR_007415.
FT   VARIANT     364    364       S -> R (in MPS3A).
FT                                /FTId=VAR_007416.
FT   VARIANT     369    369       E -> K (in MPS3A; intermediate;
FT                                dbSNP:rs104894640).
FT                                {ECO:0000269|PubMed:12702166,
FT                                ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007417.
FT   VARIANT     372    372       M -> I (in dbSNP:rs58786455).
FT                                /FTId=VAR_061884.
FT   VARIANT     374    374       Y -> H (in MPS3A).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054690.
FT   VARIANT     377    377       R -> C (in MPS3A; severe; does not yield
FT                                active enzyme; the reduction in 62 kDa
FT                                precursor and 56 kDa mature forms
FT                                suggests an increased degradation of the
FT                                mutant enzyme; dbSNP:rs772311757).
FT                                {ECO:0000269|PubMed:12000360,
FT                                ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007418.
FT   VARIANT     377    377       R -> H (in MPS3A; dbSNP:rs746037899).
FT                                /FTId=VAR_007419.
FT   VARIANT     380    380       Q -> R (in MPS3A; dbSNP:rs144143780).
FT                                /FTId=VAR_007420.
FT   VARIANT     381    381       H -> HQR (in MPS3A).
FT                                /FTId=VAR_054691.
FT   VARIANT     386    386       L -> R (in MPS3A).
FT                                {ECO:0000269|PubMed:9744479}.
FT                                /FTId=VAR_007421.
FT   VARIANT     387    387       V -> M (in dbSNP:rs62620232).
FT                                {ECO:0000269|PubMed:17128482}.
FT                                /FTId=VAR_054692.
FT   VARIANT     389    389       N -> K (in MPS3A; dbSNP:rs764057581).
FT                                /FTId=VAR_007422.
FT   VARIANT     394    394       M -> I (in dbSNP:rs34297805).
FT                                /FTId=VAR_052517.
FT   VARIANT     403    403       Missing (in MPS3A; the mutant is
FT                                enzymatically inactive; rapid degradation
FT                                rather than decrease in synthesis is
FT                                responsible for the low steady state
FT                                level of the mutant protein in cells).
FT                                {ECO:0000269|PubMed:15146460}.
FT                                /FTId=VAR_054693.
FT   VARIANT     432    435       YRAR -> W (in MPS3A).
FT                                /FTId=VAR_054694.
FT   VARIANT     433    433       R -> Q (in MPS3A; severe;
FT                                dbSNP:rs104894641).
FT                                {ECO:0000269|PubMed:12702166}.
FT                                /FTId=VAR_054695.
FT   VARIANT     433    433       R -> W (in MPS3A; the mutant is
FT                                enzymatically inactive; rapid degradation
FT                                rather than decrease in synthesis is
FT                                responsible for the low steady state
FT                                level of the mutant protein in cells; the
FT                                majority of newly synthesized protein
FT                                probably occurs in the endoplasmic
FT                                reticulum; dbSNP:rs777267343).
FT                                {ECO:0000269|PubMed:11182930,
FT                                ECO:0000269|PubMed:15146460}.
FT                                /FTId=VAR_054696.
FT   VARIANT     436    438       Missing (in MPS3A).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054697.
FT   VARIANT     447    447       E -> K (in MPS3A; dbSNP:rs104894639).
FT                                /FTId=VAR_007423.
FT   VARIANT     456    456       R -> H (does not affect enzyme activity;
FT                                cells transfected with the mutant enzyme
FT                                contain a 62 kDa precursor and a 56 kDa
FT                                mature form as cells transfected with the
FT                                wild-type enzyme; dbSNP:rs7503034).
FT                                {ECO:0000269|PubMed:11182930,
FT                                ECO:0000269|PubMed:12000360,
FT                                ECO:0000269|PubMed:12702166,
FT                                ECO:0000269|PubMed:15637719,
FT                                ECO:0000269|PubMed:9158154,
FT                                ECO:0000269|PubMed:9554748}.
FT                                /FTId=VAR_007424.
FT   VARIANT     486    486       V -> F (in MPS3A).
FT                                {ECO:0000269|PubMed:11182930}.
FT                                /FTId=VAR_054698.
FT   STRAND       24     32       {ECO:0000244|PDB:4MHX}.
FT   HELIX        38     40       {ECO:0000244|PDB:4MHX}.
FT   STRAND       43     45       {ECO:0000244|PDB:4MHX}.
FT   HELIX        48     54       {ECO:0000244|PDB:4MHX}.
FT   STRAND       57     64       {ECO:0000244|PDB:4MHX}.
FT   HELIX        70     77       {ECO:0000244|PDB:4MHX}.
FT   HELIX        83     86       {ECO:0000244|PDB:4MHX}.
FT   TURN         94     96       {ECO:0000244|PDB:4MHX}.
FT   HELIX       107    113       {ECO:0000244|PDB:4MHX}.
FT   STRAND      117    122       {ECO:0000244|PDB:4MHX}.
FT   TURN        129    131       {ECO:0000244|PDB:4MHX}.
FT   STRAND      135    139       {ECO:0000244|PDB:4MHX}.
FT   HELIX       145    149       {ECO:0000244|PDB:4MHX}.
FT   HELIX       152    164       {ECO:0000244|PDB:4MHX}.
FT   STRAND      171    176       {ECO:0000244|PDB:4MHX}.
FT   TURN        184    186       {ECO:0000244|PDB:4MHX}.
FT   HELIX       188    190       {ECO:0000244|PDB:4MHX}.
FT   TURN        195    198       {ECO:0000244|PDB:4MHX}.
FT   STRAND      199    201       {ECO:0000244|PDB:4MHX}.
FT   TURN        202    204       {ECO:0000244|PDB:4MHX}.
FT   TURN        217    219       {ECO:0000244|PDB:4MHX}.
FT   HELIX       230    259       {ECO:0000244|PDB:4MHX}.
FT   HELIX       263    265       {ECO:0000244|PDB:4MHX}.
FT   STRAND      266    274       {ECO:0000244|PDB:4MHX}.
FT   HELIX       287    290       {ECO:0000244|PDB:4MHX}.
FT   STRAND      294    297       {ECO:0000244|PDB:4MHX}.
FT   TURN        303    306       {ECO:0000244|PDB:4MHX}.
FT   STRAND      307    314       {ECO:0000244|PDB:4MHX}.
FT   HELIX       315    317       {ECO:0000244|PDB:4MHX}.
FT   HELIX       318    325       {ECO:0000244|PDB:4MHX}.
FT   STRAND      334    336       {ECO:0000244|PDB:4MHX}.
FT   HELIX       349    352       {ECO:0000244|PDB:4MHX}.
FT   STRAND      360    369       {ECO:0000244|PDB:4MHX}.
FT   STRAND      373    381       {ECO:0000244|PDB:4MHX}.
FT   STRAND      384    389       {ECO:0000244|PDB:4MHX}.
FT   TURN        390    393       {ECO:0000244|PDB:4MHX}.
FT   HELIX       400    403       {ECO:0000244|PDB:4MHX}.
FT   HELIX       406    417       {ECO:0000244|PDB:4MHX}.
FT   HELIX       427    431       {ECO:0000244|PDB:4MHX}.
FT   STRAND      435    440       {ECO:0000244|PDB:4MHX}.
FT   TURN        441    443       {ECO:0000244|PDB:4MHX}.
FT   HELIX       455    457       {ECO:0000244|PDB:4MHX}.
FT   HELIX       458    474       {ECO:0000244|PDB:4MHX}.
FT   TURN        478    484       {ECO:0000244|PDB:4MHX}.
FT   STRAND      485    487       {ECO:0000244|PDB:4MHX}.
FT   STRAND      491    497       {ECO:0000244|PDB:4MHX}.
FT   STRAND      500    502       {ECO:0000244|PDB:4MHX}.
SQ   SEQUENCE   502 AA;  56695 MW;  90C5CDAB4DCC3808 CRC64;
     MSCPVPACCA LLLVLGLCRA RPRNALLLLA DDGGFESGAY NNSAIATPHL DALARRSLLF
     RNAFTSVSSC SPSRASLLTG LPQHQNGMYG LHQDVHHFNS FDKVRSLPLL LSQAGVRTGI
     IGKKHVGPET VYPFDFAYTE ENGSVLQVGR NITRIKLLVR KFLQTQDDRP FFLYVAFHDP
     HRCGHSQPQY GTFCEKFGNG ESGMGRIPDW TPQAYDPLDV LVPYFVPNTP AARADLAAQY
     TTVGRMDQGV GLVLQELRDA GVLNDTLVIF TSDNGIPFPS GRTNLYWPGT AEPLLVSSPE
     HPKRWGQVSE AYVSLLDLTP TILDWFSIPY PSYAIFGSKT IHLTGRSLLP ALEAEPLWAT
     VFGSQSHHEV TMSYPMRSVQ HRHFRLVHNL NFKMPFPIDQ DFYVSPTFQD LLNRTTAGQP
     TGWYKDLRHY YYRARWELYD RSRDPHETQN LATDPRFAQL LEMLRDQLAK WQWETHDPWV
     CAPDGVLEEK LSPQCQPLHN EL
//
